Literature DB >> 1657307

Increase of sodium channels in demyelinated lesions of multiple sclerosis.

C Moll1, C Mourre, M Lazdunski, J Ulrich.   

Abstract

Redistribution of sodium channels along demyelinated pathways in multiple sclerosis (MS) could be an important event in restoring conduction prior to other reparative mechanisms such as remyelination. Sodium channels in human multiple sclerosis lesions were identified by quantitative light microscopic autoradiography using tritiated saxitoxin (STX), a highly specific sodium channel ligand. Demyelinated areas in various central nervous system regions containing denuded but vital axons exhibited a high increase of STX-binding sites by up to a factor of 4 as compared to normal human white matter. This important finding could explain aspects of fast clinical remissions and 'silent' MS lesions on functional and morphological properties. Demyelinated axons may functionally reorganize their membranes and adapt properties similar to those of slow conducting unmyelinated nerve fibres which have a higher amount and a more diffuse distribution of STX binding sites. This report is the first description of an altered distribution of voltage-sensitive sodium channels in human multiple sclerosis lesions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657307     DOI: 10.1016/0006-8993(91)90321-l

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  26 in total

Review 1.  Physicians, subsequence and consequence.

Authors:  W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Ion channel sequestration in central nervous system axons.

Authors:  M N Rasband; P Shrager
Journal:  J Physiol       Date:  2000-05-15       Impact factor: 5.182

3.  Visualization of nonstructural changes in early white matter development on diffusion-weighted MR images: evidence supporting premyelination anisotropy.

Authors:  D Prayer; A J Barkovich; D A Kirschner; L M Prayer; T P Roberts; J Kucharczyk; M E Moseley
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

4.  Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla.

Authors:  M Inglese; G Madelin; N Oesingmann; J S Babb; W Wu; B Stoeckel; J Herbert; G Johnson
Journal:  Brain       Date:  2010-01-27       Impact factor: 13.501

5.  Evoked potentials as a biomarker of remyelination.

Authors:  Moones Heidari; Abigail B Radcliff; Gillian J McLellan; James N Ver Hoeve; Kore Chan; Julie A Kiland; Nicholas S Keuler; Benjamin K August; Dylan Sebo; Aaron S Field; Ian D Duncan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

Review 6.  Sodium MRI of multiple sclerosis.

Authors:  Maria Petracca; Lazar Fleysher; Niels Oesingmann; Matilde Inglese
Journal:  NMR Biomed       Date:  2015-04-06       Impact factor: 4.044

Review 7.  CD8(+) T cells in multiple sclerosis.

Authors:  Aleksandar Denic; Bharath Wootla; Moses Rodriguez
Journal:  Expert Opin Ther Targets       Date:  2013-07-06       Impact factor: 6.902

8.  Deletion of beta-2-microglobulin ameliorates spinal cord lesion load and promotes recovery of brainstem NAA levels in a murine model of multiple sclerosis.

Authors:  Aleksandar Denic; Istvan Pirko; Bharath Wootla; Allan Bieber; Slobodan Macura; Moses Rodriguez
Journal:  Brain Pathol       Date:  2012-03-08       Impact factor: 6.508

Review 9.  Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis.

Authors:  B G van Engelen; D J Miller; K D Pavelko; O R Hommes; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

10.  Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger.

Authors:  Matthew J Craner; Jia Newcombe; Joel A Black; Caroline Hartle; M Louise Cuzner; Stephen G Waxman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.